KR970701047A - 진해제 및 벤지드아민을 함유하는 진해제 조성물(antitussive composition containing an antitussive and benzydamine) - Google Patents
진해제 및 벤지드아민을 함유하는 진해제 조성물(antitussive composition containing an antitussive and benzydamine)Info
- Publication number
- KR970701047A KR970701047A KR1019960704800A KR19960704800A KR970701047A KR 970701047 A KR970701047 A KR 970701047A KR 1019960704800 A KR1019960704800 A KR 1019960704800A KR 19960704800 A KR19960704800 A KR 19960704800A KR 970701047 A KR970701047 A KR 970701047A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutically acceptable
- composition
- benzidamine
- dextromethorphan
- antitussive
- Prior art date
Links
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 title claims abstract 12
- 239000000203 mixture Substances 0.000 title claims abstract 10
- 229940124584 antitussives Drugs 0.000 title claims abstract 7
- 230000000954 anitussive effect Effects 0.000 title claims abstract 6
- 229960000333 benzydamine Drugs 0.000 title claims abstract 6
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 title claims 3
- 150000003839 salts Chemical class 0.000 claims abstract 10
- 210000003169 central nervous system Anatomy 0.000 claims abstract 4
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000002253 acid Substances 0.000 claims abstract 2
- 210000000214 mouth Anatomy 0.000 claims abstract 2
- 210000004400 mucous membrane Anatomy 0.000 claims abstract 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 4
- 229960001985 dextromethorphan Drugs 0.000 claims 4
- 239000003434 antitussive agent Substances 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims 1
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 claims 1
- 229960003789 benzonatate Drugs 0.000 claims 1
- MAFMQEKGGFWBAB-UHFFFAOYSA-N benzonatate Chemical compound CCCCNC1=CC=C(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C=C1 MAFMQEKGGFWBAB-UHFFFAOYSA-N 0.000 claims 1
- 239000007910 chewable tablet Substances 0.000 claims 1
- 229940112822 chewing gum Drugs 0.000 claims 1
- 235000015218 chewing gum Nutrition 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 1
- 229960000920 dihydrocodeine Drugs 0.000 claims 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 1
- -1 dimemorpan Chemical compound 0.000 claims 1
- 229960000520 diphenhydramine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical compound O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229960003221 levopropoxyphene Drugs 0.000 claims 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 claims 1
- 229960004708 noscapine Drugs 0.000 claims 1
- 235000010603 pastilles Nutrition 0.000 claims 1
- 229960003436 pentoxyverine Drugs 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
본 발명은 함유된 성분을 구강의 점막과 보다 현저하게 접촉되게 하고, 중추신경계 작용 진해제 또는 이의 약제학적으로 허용되는 염 및 벤지드아민 또는 이의 약제학적으로 허용하는 산부가염을 포함함을 특징으로 하는 조성물에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (8)
- 함유된 성분을 구강의 점막과 보다 현저하게 접촉되게 하고, 중추신경계 작용 진해제 또는 이의 약제학적으로 허용되는 염 및 벤지드아민 또는 이의 약제학적으로 허용하는 산부가염을 포함함을 특징으로 하는 경구용의 약제학적 진해제 조성물.
- 제1항에 있어서, 향정, 스위트, 씹을 수 있는 정제 또는 츄잉검 형태인 조성물.
- 제1항 또는 제2항에 있어서, 코데인, 덱스트로메토르판, 디하이드로코데인, 디메모르판, 노스카핀, 레보프로폭시펜 납실레이트, 카르베타펜탄, 카라미펜, 클로페디아놀, 디펜하이드라민, 글라우신, 벤조나테이트, 하이드로코돈, 하이드로모르폰 및 이들의 약제학적으로 허용되는 염중에서 선택된 중추신경계 작용 진해제를 표준용량의 0.5 내지 2배로 함유함을 특징으로 하는 조성물.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 중추신경계 작용 진해제 중량의 1/200 내지 2배 양의 벤지드아민 또는 동일한 양의 이의 약제학적으로 허용되는 부가염을 포함함을 특징으로 하는 조성물.
- 제1항에 있어서, 0.15 내지 10㎎의 벤지드아민, 및 5 내지 30㎎의 덱스트로메토르판 또는 동일한 양의 이의 약제학적으로 허용되는 염을 포함함을 특징으로 하는 조성물.
- 제5항에 있어서, 벤지드아민의 약제학적으로 허용되는 염이 하이드로클로라이드임을 특징으로 하는 조성물.
- 제5항 또는 제6항에 있어서, 덱스트로메토르판의 약제학적으로 허용되는 염이 하이드로브로미드임을 특징으로 하는 조성물.
- 제5항 또는 제6항에 있어서, 덱스트로메토르판의 약제학적으로 허용되는 염이 하이드로브로미드 수화물임을 특징으로 하는 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI94A000362 | 1994-03-01 | ||
| ITMI940362A IT1274026B (it) | 1994-03-01 | 1994-03-01 | Composizione antitosse |
| PCT/EP1995/000658 WO1995023602A1 (en) | 1994-03-01 | 1995-02-22 | Antitussive composition containing an antitussive and benzydamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970701047A true KR970701047A (ko) | 1997-03-17 |
Family
ID=11368015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960704800A KR970701047A (ko) | 1994-03-01 | 1995-02-22 | 진해제 및 벤지드아민을 함유하는 진해제 조성물(antitussive composition containing an antitussive and benzydamine) |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US5932589A (ko) |
| EP (1) | EP0748222B1 (ko) |
| JP (1) | JP3348858B2 (ko) |
| KR (1) | KR970701047A (ko) |
| CN (1) | CN1088358C (ko) |
| AT (1) | ATE195074T1 (ko) |
| AU (1) | AU681257B2 (ko) |
| BR (1) | BR9506956A (ko) |
| CA (1) | CA2184594C (ko) |
| CZ (1) | CZ284798B6 (ko) |
| DE (1) | DE69518229T2 (ko) |
| DK (1) | DK0748222T3 (ko) |
| ES (1) | ES2149969T3 (ko) |
| FI (1) | FI963394A (ko) |
| GR (1) | GR3034665T3 (ko) |
| HU (1) | HUT75937A (ko) |
| IT (1) | IT1274026B (ko) |
| NO (1) | NO309965B1 (ko) |
| NZ (1) | NZ281230A (ko) |
| PL (1) | PL178608B1 (ko) |
| PT (1) | PT748222E (ko) |
| RO (1) | RO117147B1 (ko) |
| RU (1) | RU2143901C1 (ko) |
| SK (1) | SK282567B6 (ko) |
| UA (1) | UA37278C2 (ko) |
| WO (1) | WO1995023602A1 (ko) |
| ZA (1) | ZA951588B (ko) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124282A (en) * | 1997-05-22 | 2000-09-26 | Sellers; Edward M. | Drug formulations |
| CA2314893C (en) * | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
| US7138133B2 (en) | 2001-10-10 | 2006-11-21 | The Procter & Gamble Company | Orally administered liquid compositions |
| WO2003089007A1 (en) * | 2002-04-22 | 2003-10-30 | Adcock Ingram Intellectual Property (Proprietary) Limited | Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu |
| PL1848403T3 (pl) * | 2005-01-14 | 2010-09-30 | Camurus Ab | Preparaty bioadhezyjne o działaniu miejscowym |
| SI1845942T1 (sl) * | 2005-01-14 | 2014-06-30 | Camurus Ab | Gnrh analogne formulacije |
| CN101219140B (zh) * | 2007-12-24 | 2011-06-01 | 重庆市莱美药物技术有限公司 | 盐酸苄达明可溶片及其制备方法 |
| SI2451452T1 (sl) | 2009-07-08 | 2015-12-31 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. | Uporaba benzidamina pri zdravljenju bolezni, odvisnih od p40 |
| CA2904045C (en) * | 2013-03-13 | 2022-03-29 | Tris Pharma, Inc. | Benzonatate modified release solid tablets and capsules |
| CA2976187A1 (en) * | 2015-02-09 | 2016-08-18 | Cellix Bio Private Limited | Benzydamine salts and compositions thereof useful for the treatment of mucositis |
| US11214544B2 (en) | 2017-04-14 | 2022-01-04 | Kempharm, Inc. | Dextrorphan prodrugs and processes for making and using them |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196436A (en) * | 1990-10-31 | 1993-03-23 | The Procter & Gamble Company | Dextromethorphan antitussive compositions |
| EP0555411A1 (en) * | 1990-10-31 | 1993-08-18 | The Procter & Gamble Company | Dextromethorphan antitussive compositions |
-
1994
- 1994-03-01 IT ITMI940362A patent/IT1274026B/it active IP Right Grant
-
1995
- 1995-02-22 CN CN95191917A patent/CN1088358C/zh not_active Expired - Fee Related
- 1995-02-22 PT PT95909772T patent/PT748222E/pt unknown
- 1995-02-22 PL PL95316079A patent/PL178608B1/pl not_active IP Right Cessation
- 1995-02-22 KR KR1019960704800A patent/KR970701047A/ko not_active Application Discontinuation
- 1995-02-22 CA CA002184594A patent/CA2184594C/en not_active Expired - Fee Related
- 1995-02-22 AT AT95909772T patent/ATE195074T1/de not_active IP Right Cessation
- 1995-02-22 ES ES95909772T patent/ES2149969T3/es not_active Expired - Lifetime
- 1995-02-22 CZ CZ962532A patent/CZ284798B6/cs not_active IP Right Cessation
- 1995-02-22 AU AU18116/95A patent/AU681257B2/en not_active Ceased
- 1995-02-22 UA UA96093730A patent/UA37278C2/uk unknown
- 1995-02-22 WO PCT/EP1995/000658 patent/WO1995023602A1/en active IP Right Grant
- 1995-02-22 HU HU9602390A patent/HUT75937A/hu unknown
- 1995-02-22 DK DK95909772T patent/DK0748222T3/da active
- 1995-02-22 DE DE69518229T patent/DE69518229T2/de not_active Expired - Fee Related
- 1995-02-22 NZ NZ281230A patent/NZ281230A/en not_active IP Right Cessation
- 1995-02-22 US US08/700,362 patent/US5932589A/en not_active Expired - Fee Related
- 1995-02-22 RO RO96-01736A patent/RO117147B1/ro unknown
- 1995-02-22 JP JP52267395A patent/JP3348858B2/ja not_active Expired - Fee Related
- 1995-02-22 SK SK1085-96A patent/SK282567B6/sk unknown
- 1995-02-22 EP EP95909772A patent/EP0748222B1/en not_active Expired - Lifetime
- 1995-02-22 RU RU96120415A patent/RU2143901C1/ru not_active IP Right Cessation
- 1995-02-22 BR BR9506956A patent/BR9506956A/pt not_active IP Right Cessation
- 1995-02-24 ZA ZA951588A patent/ZA951588B/xx unknown
-
1996
- 1996-08-30 FI FI963394A patent/FI963394A/fi not_active Application Discontinuation
- 1996-08-30 NO NO963634A patent/NO309965B1/no not_active IP Right Cessation
-
2000
- 2000-10-23 GR GR20000402355T patent/GR3034665T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2414084T3 (es) | Sistema de administración de fármacos por vía transmucosa | |
| US4661492A (en) | Analgesic compositions | |
| US5196436A (en) | Dextromethorphan antitussive compositions | |
| CA2392013C (en) | Analgesic compositions containing buprenorphine in combination with naloxone, naltrexone or nalmefene | |
| KR870002832A (ko) | 제약 조성물 | |
| PL324988A1 (en) | Orally administered readily dissolving compositions for dopamine antagonists | |
| WO2003013433A3 (en) | Sequestered antagonist formulations | |
| KR900015737A (ko) | 배합물 | |
| US4829056A (en) | Buccal tablet comprising etorphine or a salt thereof | |
| KR970701047A (ko) | 진해제 및 벤지드아민을 함유하는 진해제 조성물(antitussive composition containing an antitussive and benzydamine) | |
| RU96120415A (ru) | Противокашлевая композиция, содержащая противокашлевое средство и бензидамин | |
| CA1333773C (en) | Antitussive liquid compositions containing phenol | |
| US3560625A (en) | Method of,and formulations for,introducing alkoxybenzamides into the systemic circulatory system | |
| HUT64216A (en) | Process for producing cough diminishing medical preparative containing dextrometorphane | |
| JPH10316568A (ja) | 医薬組成物 | |
| MXPA96003747A (en) | Antitus composition | |
| JPH11302189A (ja) | 感冒用組成物 | |
| Langman | Gastrointestinal drugs | |
| WO2004108092A2 (en) | Tannate compositions and methods of use | |
| JP2006062999A (ja) | カフェイン含有カプセル製剤 | |
| MXPA96006041A (en) | Dosage form of rapida disoluc |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |